S-MEPHENYTOIN HYDROXYLATION PHENOTYPES IN A SWEDISH POPULATION DETERMINED AFTER COADMINISTRATION WITH DEBRISOQUIN

被引：139
作者：
SANZ, EJ [1 ]
VILLEN, T [1 ]
ALM, C [1 ]
BERTILSSON, L [1 ]
机构：
[1] KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1989年 / 45卷 / 05期
关键词：
D O I：
10.1038/clpt.1989.63
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：495 / 499
页数：5
相关论文
共 28 条
[1]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[2]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[3]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186
[4]  
GUT J, 1986, J BIOL CHEM, V261, P1734
[5]   MEPHENYTOIN AND SPARTEINE PHARMACOGENETICS IN CANADIAN CAUCASIANS [J].
INABA, T ;
JURIMA, M ;
NAKANO, M ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) :670-676
[6]   MEPHENYTOIN HYDROXYLATION IN THE CUNA AMERINDIANS OF PANAMA [J].
INABA, T ;
JORGE, LF ;
ARIAS, TD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (01) :75-79
[7]  
INABA T, 1985, DRUG METAB DISPOS, V13, P443
[8]   SPARTEINE OXIDATION BY THE HUMAN-LIVER - ABSENCE OF INHIBITION BY MEPHENYTOIN [J].
JURIMA, M ;
INABA, T ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (03) :426-428
[9]  
KNODELL RG, 1987, J PHARMACOL EXP THER, V241, P1112
[10]  
KNODELL RG, 1988, J PHARMACOL EXP THER, V245, P845
123